[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Quest Diagnostics Inc (DGX)

Quest Diagnostics Inc (DGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,041,404
  • Shares Outstanding, K 110,373
  • Annual Sales, $ 11,035 M
  • Annual Income, $ 992,000 K
  • EBIT $ 1,781 M
  • EBITDA $ 2,351 M
  • 60-Month Beta 0.58
  • Price/Sales 2.32
  • Price/Cash Flow 15.28
  • Price/Book 3.27

Options Overview Details

View History
  • Implied Volatility 25.50% (+0.08%)
  • Historical Volatility 32.20%
  • IV Percentile 63%
  • IV Rank 37.90%
  • IV High 39.24% on 07/22/26
  • IV Low 17.11% on 08/15/25
  • Expected Move (DTE 22) 11.05 (4.70%)
  • Put/Call Vol Ratio 20.57
  • Today's Volume 906
  • Volume Avg (30-Day) 1,041
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 12,405
  • Open Int (30-Day) 9,251
  • Expected Range 224.17 to 246.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.82
  • Number of Estimates 8
  • High Estimate $2.90
  • Low Estimate $2.72
  • Prior Year $2.60
  • Growth Rate Est. (year over year) +8.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
201.00 +17.02%
on 07/16/26
240.13 -2.04%
on 07/28/26
+22.58 (+10.62%)
since 06/29/26
3-Month
186.23 +26.31%
on 05/08/26
240.13 -2.04%
on 07/28/26
+45.90 (+24.24%)
since 04/29/26
52-Week
166.75 +41.06%
on 07/30/25
240.13 -2.04%
on 07/28/26
+67.29 (+40.07%)
since 07/29/25

Most Recent Stories

More News
Quest’s (NYSE:DGX) Q2 CY2026: Beats On Revenue, Stock Soars

Quest’s (NYSE:DGX) Q2 CY2026: Beats On Revenue, Stock Soars

DGX : 235.22 (-0.31%)
Quest Diagnostics: Q2 Earnings Snapshot

Quest Diagnostics: Q2 Earnings Snapshot

DGX : 235.22 (-0.31%)
Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

SECAUCUS, N.J. , July 23, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second...

DGX : 235.22 (-0.31%)
Quest Diagnostics Reports Earnings the Same Day It Pays Shareholders Their Quarterly Dividend

Barchart Research What to Expect from DGX Earnings DGX Generated July 22, 2026 Current Price $209.83 EPS Estimate $$2.81 Consensus Rating Moderate Buy Average Move 5.69% Quest Diagnostics Reports Earnings...

DGX : 235.22 (-0.31%)
One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

SECAUCUS, N.J. , July 10, 2026 /PRNewswire/ -- Nearly one in five workers in the general U.S. workforce (19.1%) tested positive for drug use based on an analysis of hair specimens collected in 2025,...

DGX : 235.22 (-0.31%)
Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI

American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD

DGX : 235.22 (-0.31%)
Digi Power X Provides Operations and Financial Update

MIAMI, FL / ACCESS Newswire / July 7, 2026 / Digi Power X Inc. (NASDAQ:DGXX)(Cboe Canada:DGX) (the "Company" and "Digi Power X"), an AI data center infrastructure operator, today provided an update on...

DGX : 235.22 (-0.31%)
DGX.NE : 4.6000 (-10.51%)
DGX.VN : 3.790 (+5.28%)
DGXX : 3.30 (-10.08%)
Quest Diagnostics's Q2 2026 Earnings: What to Expect

Quest Diagnostics is expected to unveil its second-quarter results later this month, and analysts expect a single-digit growth in earnings.

ABT : 108.00 (+0.68%)
XLV : 166.24 (-0.61%)
DGX : 235.22 (-0.31%)
$SPX : 7,316.15 (-1.52%)
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers

DGX : 235.22 (-0.31%)
Is Quest Diagnostics Stock Underperforming the S&P 500?

While Quest Diagnostics has lagged behind the S&P 500 Index over the past year, analysts are moderately optimistic about the stock’s prospects.

DGX : 235.22 (-0.31%)
$SPX : 7,316.15 (-1.52%)
TMO : 576.46 (+0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services...

See More

Key Turning Points

3rd Resistance Point 242.55
2nd Resistance Point 240.20
1st Resistance Point 237.71
Last Price 235.22
1st Support Level 232.86
2nd Support Level 230.51
3rd Support Level 228.02

See More

52-Week High 240.13
Last Price 235.22
Fibonacci 61.8% 212.10
Fibonacci 50% 203.44
Fibonacci 38.2% 194.78
52-Week Low 166.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.